EU/3/17/1960: Orphan designation for the treatment of congenital erythropoietic porphyria

Ciclopirox

Table of contents

Overview

On 17 January 2018, orphan designation (EU/3/17/1960) was granted by the European Commission to Atlas Molecular Pharma S.L., Spain, for ciclopirox for the treatment of congenital erythropoietic porphyria.

Key facts

Active substance
Ciclopirox
Intended use
Treatment of congenital erythropoietic porphyria
Orphan designation status
Positive
EU designation number
EU/3/17/1960
Date of designation
17/01/2018
Sponsor
Atlas Molecular Pharma S.L.
Parque Tecnológico de Bizkaia
Building 800
48160 Derio
Spain
Tel. +34 9465 72504
E-mail: info@atlasmolecularpharma.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating